The brief viability of organs creates a logistical nightmare. Surgeons fly on chartered jets to retrieve organs, while recipients must remain within a small radius of the hospital, unable to travel. Cryopreservation's immediate impact would be to remove time as a variable, allowing for scheduled surgeries and a more humane patient experience.

The use of pigs for human transplants stems from a historical partnership between the Mayo Clinic and Hormel Foods to breed smaller 'minipigs' for lab research. This agricultural project, combined with pigs' anatomical similarities and lower disease-transmission risk compared to primates, established them as the primary source for replacement organs.

Non-human primate models are poor predictors of human immunogenicity. The industry has shifted to human-relevant ex vivo assays using whole blood or PBMCs. These tests can assess risks like complement activation upfront, enabling proactive protein engineering to improve a drug's safety profile.

Unlike external machines, implanting parts internally triggers the body's powerful defenses. The immune system attacks foreign objects, and blood forms clots around non-native surfaces. These two biological responses are the biggest design hurdles for internal replacement parts, problems that external devices like dialysis machines don't face.

Unlike direct-to-patient cell therapies, xenotransplantation's process of creating a pig serves as a biological filter. If gene edits have significant off-target effects, a healthy animal cannot be produced. This 'viable animal' checkpoint validates the genetic engineering before clinical use.

A major unknown was the surgical procedure itself. After four cases, surgeons report that transplanting a pig kidney is remarkably similar to a human-to-human allogeneic transplant. This de-risks the surgical component significantly, with patients often leaving the ICU in one night.

Instead of using large commercial pigs and then editing genes to limit organ growth, eGenesis selected the Yucatan mini-pig breed from the start. This breed's organs naturally grow to a size compatible with human recipients, simplifying the genetic engineering required.

Unlike cell-line derived (CDX) models, PDX models are grown directly from patient samples without a culture phase. This preserves the original tumor's heterogeneity, leading to more clinically relevant and predictive data in preclinical radiopharmaceutical studies.

eGenesis views success not as lifelong replacement but as buying patients time. One recipient of a pig kidney lived with it for nine months, recovered health, and then successfully received a human kidney, proving the value of xenotransplantation as a bridge therapy.